1. Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120.
- Author
-
Chirenje, Zvavahera, Laher, Fatima, Dintwe, One, Muyoyeta, Monde, deCamp, Allan, He, Zonglin, Grunenberg, Nicole, Laher Omar, Faatima, Seaton, Kelly, Polakowski, Laura, Woodward Davis, Amanda, Maganga, Lucas, Baden, Lindsey, Mayer, Kenneth, Kalams, Spyros, Keefer, Michael, Edupuganti, Srilatha, Rodriguez, Benigno, Frank, Ian, Scott, Hyman, Stranix-Chibanda, Lynda, Gurunathan, Sanjay, Koutsoukos, Marguerite, Van Der Meeren, Olivier, DiazGranados, Carlos, Paez, Carmen, Andersen-Nissen, Erica, Kublin, James, Corey, Lawrence, Ferrari, Guido, Tomaras, Georgia, and McElrath, M
- Subjects
HIV ,adjuvant ,dose ,vaccine ,Humans ,Female ,Adjuvants ,Immunologic ,AIDS Vaccines ,Adult ,Male ,Young Adult ,HIV Infections ,HIV Envelope Protein gp120 ,Adolescent ,Double-Blind Method ,HIV Antibodies ,Squalene ,Polysorbates ,HIV-1 ,Viral Vaccines - Abstract
BACKGROUND: HVTN 120 is a phase 1/2a randomized double-blind placebo-controlled human immunodeficiency virus (HIV) vaccine trial that evaluated the safety and immunogenicity of ALVAC-HIV (vCP2438) and MF59- or AS01B-adjuvanted bivalent subtype C gp120 Env protein at 2 dose levels in healthy HIV-uninfected adults. METHODS: Participants received ALVAC-HIV (vCP2438) alone or placebo at months 0 and 1. At months 3 and 6, participants received either placebo, ALVAC-HIV (vCP2438) with 200 μg of bivalent subtype C gp120 adjuvanted with MF59 or AS01B, or ALVAC-HIV (vCP2438) with 40 μg of bivalent subtype C gp120 adjuvanted with AS01B. Primary outcomes were safety and immune responses. RESULTS: We enrolled 160 participants, 55% women, 18-40 years old (median age 24 years) of whom 150 received vaccine and 10 placebo. Vaccines were generally safe and well tolerated. At months 6.5 and 12, CD4+ T-cell response rates and magnitudes were higher in the AS01B-adjuvanted groups than in the MF59-adjuvanted group. At month 12, HIV-specific Env-gp120 binding antibody response magnitudes in the 40 μg gp120/AS01B group were higher than in either of the 200 μg gp120 groups. CONCLUSIONS: The 40 μg dose gp120/AS01B regimen elicited the highest CD4+ T-cell and binding antibody responses. Clinical Trials Registration . NCT03122223.
- Published
- 2024